Albert Labs International Corp. (CSE:ABRT)
Canada · Delayed Price · Currency is CAD 0.0050
0.00 (0.00%)
Jul 15, 2024, 9:38 AM EDT
Albert Labs International Company Description
Albert Labs International Corp., a biopharmaceutical drug discovery company, researches and develops drugs for psychedelic-assisted therapy for patients with urgent and unmet needs in Canada and the United Kingdom.
It develops KRN-101, is a solution for cancer-related anxiety. The company is based in Burnaby, Canada.
Albert Labs International Corp.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Navchand Jagpal |
Contact Details
Address: 201-6996 Merritt Avenue Burnaby, V5J 4R6 Canada | |
| Phone | 778 819 0740 |
| Website | albertlabs.com |
Stock Details
| Ticker Symbol | ABRT |
| Exchange | Canadian Securities Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA0127841041 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Navchand Jagpal | Acting Chief Executive Officer, Chief Financial Officer and Director |
| Santoke Naal | Chief Operating Officer |
| Toby Sorabjee | Chief Communications Officer |
| Dr. Malcolm Barratt-Johnson | Chief Medical Officer |